USPTO Patent Applications - Biotech (C12N)

Rabbit Antigen Binding Protein Nucleic Acid Libraries and Methods

USPTO published patent application US20260110113A1 for rabbit-derived antigen binding protein nucleic acid libraries that specifically recognize target peptide-MHC (pMHC) complexes. Inventors include Anna Maria Sobieraj, Severin Oliver Wendelspiess, and Fabian Bert Scheifele. The application was filed September 5, 2025, with CPC classifications covering C40B, C12N, and C07K technology areas.

Natera Patent Application on Xenotransplant Rejection Detection Methods

Natera, Inc. has filed US Patent Application US20260110032A1 disclosing methods for detecting and monitoring xenotransplant rejection by extracting and measuring cell-free DNA, RNA, or proteins derived from the xenotransplant in recipient biological samples. The methods enable rejection assessment through sequencing library preparation and whole genome sequencing analysis of donor-derived biomarkers. Transplant centers, biotech researchers, and diagnostics developers in the organ transplantation space should monitor this intellectual property filing.

Gen-Probe Patent, Magnetic Bead Lysis in Fluidic Cartridge

Gen-Probe Incorporated filed US Patent Application US20260110020A1 on December 18, 2025, describing a fluidic cartridge system for lysing cells using magnetic agitation of non-magnetic beads combined with a magnetic element. The invention incorporates an internal control reagent deposited on beads and the magnetic element to validate assay results and cell lysis effectiveness. The magnetic field causes controlled movement of the magnetic element and non-magnetic beads, which mechanically lyses cells and releases nucleic acids, while the internal control distributes throughout the fluid sample. Inventors Byron J. Knight, Norbert D. Hagen, and David Opalsky are named on the application.

Methods and Systems for Long-Range Methylation Profiling

Moonwalk Biosciences, Inc. has filed patent application US20260110025A1, published April 23, 2026, covering methods and systems for determining epigenetic profiles of cells in a cell population. The technology involves sequencing DNA molecules to provide sequence reads with methylation status, assembling contigs from overlapping sequence reads, and identifying contigs with different methylation profiles associated with different cells. The application was filed December 29, 2023, under Application No. 19144874. Biotech and pharmaceutical companies developing single-cell epigenomics tools or precision medicine diagnostics may want to review this filing for potential freedom-to-operate considerations.

Compositions and Methods for Enzymatic Production of Polyphenol Aglycone Compounds

USPTO published patent application US20260110012A1 on April 23, 2026, covering glycoside hydrolase compositions and methods for enzymatic production of polyphenol aglycone compounds. The application (filed October 17, 2025, Application No. 19361768) names inventors Jose A. Amaya, Jeffrey Ehrhardt, Jingyi Li, and Drew Taylor Wagner, and includes CPC classifications C12P 19/46, C12N 9/2402, and C12P 19/14. Patent applications are published to inform the public and initiate the examination process; they do not yet confer enforceable patent rights.

Nucleic Acid siRNA Anti-Hair Loss Patent Application

The USPTO has published patent application US20260109987A1, filed October 21, 2025, by CANAAN PARTNERS INC. and ten named inventors, covering a siRNA composition that silences the androgen receptor (AR) gene for anti-hair loss and oil control effects, combined with an ionic liquid delivery system enabling transdermal penetration to the dermis layer. The application also claims antibacterial activity against Propionibacterium acnes. CPC classifications include C12N 15/1138, A61K 47/186, and A61P 17/14.

Therapeutic Oligonucleotides for Cystic Fibrosis Mutations

USPTO published patent application US20260109986A1 on April 23, 2026, filed by applicants on October 13, 2023 (application no. 19117758). The application discloses therapeutic splice-switching oligonucleotides designed to correct specific CFTR gene mutations including 1811+1.6kb G>T, 1811+1.6kb A>G, 1811+1.6kb T>A, and W1282X, for the treatment of cystic fibrosis in a subject. Inventors: Silvia Kreda, Yan Dang, Aiguo Ni. This is a routine patent publication creating no compliance obligations.

MAPT Targeting Oligonucleotides for Neurodegenerative Disease Treatment

USPTO published patent application US20260109982A1 on April 23, 2026, filed September 24, 2025 (application no. 19338285), disclosing novel MAPT targeting sequences and MAPT targeting oligonucleotides for the treatment of neurodegenerative diseases. Four inventors are named: Anastasia Khvorova, Chantal Ferguson, Sarah Davis, and Kathryn Monopoli. The CPC classifications indicate this is a biotechnology/pharmaceutical invention (C12N 15/113, A61P 25/28).

Synthetic Engineered RNA Molecules and Related Methods

USPTO published patent application US20260109976A1 filed by Kristine Bielecki and Devan Shah on May 28, 2025, covering heterologous engineered mRNA molecules designed to increase expression profiles. The application, assigned number 19221434 and published April 23, 2026, includes CPC classifications spanning C12N biochemistry and A61K pharmaceutical preparation categories. Patent rights, if granted, would provide exclusivity over the synthetic engineered mRNA constructs and associated production methods.

TriLink BioTechnologies Modified RNA With 3′-Stabilizing Region

TriLink BioTechnologies, LLC has filed US Patent Application US20260109977A1 covering modified RNA molecules where a 3′-stabilizing region is covalently attached to the RNA, and where the 3′-stabilizing region comprises one or more modified nucleosides. The application (No. 19386605) was filed on November 12, 2025, and names eight inventors: Chunping Xu, Chanfeng Zhao, Paul Theodore Ludford III, Dhamodharan Venugopal, Alexandre V. Lebedev, and Hengyuan Lang. This biotechnology patent application relates to methods for increasing protein expression through modified RNA design.

RNA-Guided DNA Integration Using Tn7-Like Transposons

The USPTO published patent application US20260109980A1 filed by Samuel Henry Sternberg and Sanne Eveline Klompe on May 8, 2025, covering systems and methods that use Tn7-like transposons encoding CRISPR-Cas systems for programmable, RNA-guided DNA integration downstream of a genomic target site. The application claims priority to CPC classifications including C12N 15/113, C12N 9/22, and C12N 15/902. Parties researching gene-editing technologies involving transposon-based integration should monitor this application for competitive landscape implications.

Nucleic Acid Regulatory Elements Enhance Gene Expression

The USPTO published patent application US20260109978A1, filed October 11, 2023 (Application No. 19117712), covering nucleic acid regulatory elements designed to enhance constitutive gene expression across multiple tissue types including liver, muscle, and the central nervous system. The application names eight inventors and discloses expression cassettes, vectors, and methods particularly suited for gene therapy applications. The patent publication makes the application publicly accessible but does not constitute a granted patent right.

shRNA Targeting Sav1 Gene for Cardiomyocyte Renewal (US20260109983A1)

Baylor College of Medicine has filed US Patent Application US20260109983A1, published April 23, 2026, covering methods and compositions for cardiomyocyte renewal using shRNA molecules targeting the Sav1 gene within the Hippo signaling pathway. The application names James F. Martin, Yuka Morikawa, Todd Ryan Heallen, and John P. Leach as inventors, with a filing date of October 31, 2025 and application number 19376011. CPC classifications include C12N 15/113, A61K 31/713, and related genetic therapy categories.

Gene Therapy Trans-Splicing OPA1 Mutations

Centre National de la Recherche Scientifique has filed USPTO Patent Application US20260109985A1 (application No. 19116221, originally filed September 29, 2023) covering pre-mRNA trans-splicing molecules (RTMs) designed to correct mutations in the OPA1 gene, with claims extending to both ex vivo and in vivo gene therapy methods for treating diseases associated with OPA1 mutations. The application names five inventors: Yannick Le Dantec, Guy Lenaers, Olivier Baris, Arnaud Chevrollier, and Salim Khiati. CPC classifications include C12N 15/1137 (DNA/RNA therapeutic compositions) and C12N 15/86 (viral vectors). This publication makes the application publicly available for prior art and freedom-to-operate analysis; no patent rights are granted until the application is examined and allowed.

Nucleic Acid Regulatory Elements for Liver Gene Expression

USPTO published patent application US20260109979A1 for nucleic acid regulatory elements (NAREs) that enhance gene expression in liver tissue. The application covers expression cassettes and vectors containing these elements for gene therapy applications, filed October 11, 2023 under application number 19117793. Named inventors include Alexandria Forbes, Josefa Sullivan, Chenjin Jin, Enrico Mossotto, Matthew During, Ce Feng Liu, Dustin Lee, and Jessica Schmerler.

NORAD RNA Treatment for Beta-Thalassemia, Sickle Cell Disease

USPTO published patent application US20260109984A1 for therapeutic methods, systems, and compositions treating hemoglobinopathies including beta-thalassemia and sickle cell disease by increasing expression of noncoding RNA activated by DNA damage (NORAD). The application was filed on 2025-10-28 under application number 19371206, with inventors Merlin Nithya Gnanapragasam and Mahesh Ramamoorthy. Overexpression of NORAD long non-coding RNA is shown to increase fetal hemoglobin expression, providing a therapeutic approach for these genetic blood disorders.

Cellular Compositions and Methods of Treatment I

The USPTO published patent application US20260109981A1 on April 23, 2026, covering cellular compositions modified to deliver nucleic acids to target cells for the treatment of diseases including cancer. The application, filed September 16, 2025, names 11 inventors including Peter Brink, Ira Cohen, Richard Lin, and others. CPC classifications indicate focus areas in nucleic acid delivery, cell-based therapies, and oncology applications.

Nucleic Acid Adapter Methods and Template Switching Compositions

USPTO patent application US20260109971A1 for nucleic acid adapter methods and template switching compositions was published on April 23, 2026. The application, filed October 20, 2025 (Application No. 19363300), names Craig Betts, Steve Oh, George G. Jokhadze, and Nathalie Bolduc as inventors. The published application covers methods of adding adapters to nucleic acids involving template RNA, template switch oligonucleotides, polymerases, and dNTPs in reaction mixtures.

Single Cell Library Construction with Tissue Location Data

Beijing SeekGene Biosciences Co., Ltd. filed US Patent Application US20260109969A1 for a method of constructing a single cell library containing tissue location information and an associated sequencing method, published April 23, 2026. The application names eight inventors and describes a five-step process enabling simultaneous analysis of spatial location and genetic information at the single cell level. Patent prosecution would determine whether claims covering the chip-based binding, tissue dissociation, and high-throughput library construction method are allowed.

Pseudo-Viral Systems Map Viral Protein Resistance Mutations

The USPTO has published patent application US20260109967A1 for pseudo-viral systems designed for mutational scanning of viral proteins, assigned to Fred Hutchinson Cancer Center. The application (No. 19120534) describes cell-stored barcoded viral protein libraries that can map resistance mutations to therapeutic treatments. The publication date is April 23, 2026, with a filing date of October 12, 2023.

Oligonucleotide Synthesis Method, USPTO, 23rd Apr

USPTO published patent application US20260109968A1 on April 23, 2026, filed August 31, 2023, for a method enabling simultaneous synthesis of a plurality of oligonucleotide molecules. The application names five inventors: Omer Ziv, Cameron Thorpe, Arun Tanpure, and Yaniv Erlich. The disclosed orthogonal synthesis technique applies to combinatorial chemistry and DNA-encoded library (DEL) applications.

Multi-Partite CRISPR Editors, High-Throughput Discovery Methods

US Patent Application US20260109972A1, filed November 9, 2023, has been published by the USPTO, disclosing multi-partite CRISPR-based editor compositions and high-throughput methods for discovering polypeptides with editing activity. Inventors include Luke A. Gilbert, Greg Pommier, Jonathan Weissman, and Caroline Wilson. The publication makes the application's technical disclosure publicly accessible as prior art.

High-Throughput Combinatorial Screening System for Optimized Cas9 Variants

US20260109973A1 is a published USPTO patent application filed on August 21, 2025, covering a high-throughput combinatorial genetic modification system and optimized SpCas9 enzyme variants produced by that system. The application names Alan Siu Lun Wong and Gigi Ching Gee Choi as inventors and was published on April 23, 2026. As a published application, the invention enters the public record, establishing a priority date and initiating the examination process toward grant.

cDNA Library Interaction Testing Method, HuBei Hongshan Laboratory

US Patent Application US20260109966A1, published April 23, 2026, discloses a method for preparing an interaction plasmid library and a method for testing interactions between cDNA libraries. The cDNA libraries are insertable into the first multiple cloning site and the second multiple cloning site of a dual expression vector for testing interactions between different cDNA libraries. Filed by HuBei Hongshan Laboratory (Application No. 19000135, filed December 23, 2024) with inventors Lin Li and Xiaoyang Shang.

Biomolecule Retention Patent 11 Inventors Published Apr 23

The USPTO has published patent application US20260109974A1 titled 'SYSTEMS AND METHODS FOR BIOMOLECULE RETENTION,' filed on December 22, 2025, with 11 named inventors including Torri Elise Rinker, Christina Inman, and Parag Mallick. The application covers compositions, systems, and methods for displaying analytes such as biomolecules by coupling them to displaying molecules configured to associate with surfaces or interfaces, enabling formation of analyte arrays for assays. CPC classifications include C12N, B01J, B82Y, and C12Q categories related to molecular biology and analytical techniques.

Self-Replicating RNA Molecule with Mosso das Pedras Virus-Derived RNA Replicase

Nanjing Genscript Biotech Co., Ltd. has received USPTO Patent Application US20260109975A1 (publication date April 23, 2026; application filed January 24, 2025 under application number 19155923) covering a self-replicating RNA molecule with a defined 5-prime-to-3-prime structure including a 5-prime cap, 5-prime UTR, open reading frame encoding an RNA replicase, a promoter, a sequence of interest, a 3-prime UTR, and a poly(A) tail. The RNA replicase is a nonstructural protein or functional variant derived from one of 13 named viruses including Mosso das Pedras virus (MDPV), Everglades virus (EVEV), Rio Negro virus (RNV), Mucambo virus (MUCV), Highlands J virus (HJV), Pixuna virus (PIXV), Trocara virus (TROV), Cabassou virus (CABV), Tonate virus (TONV), Bebaru virus (BEBV), Fort Morgan virus (FMV), Getah virus (GETV), or Ndumu virus (NDUV).

Magnetic Hydrogel Particles for Chemical, Biological Synthesis

USPTO published patent application US20260109970A1 on April 23, 2026, filed by inventors Brian PAEGEL and Valerie CAVETT on July 29, 2025 (Application No. 19284375). The invention covers magnetic core particles coated in a polymeric gel designed to support both chemical and biological synthesis operations. Patent applications do not create compliance obligations but establish priority rights and public notice of claimed innovations for interested parties to evaluate freedom-to-operate.

CJ Cheiljedang L-Alanine Polynucleotide Patent Application

CJ Cheiljedang Corporation filed patent application US20260109957A1 on December 12, 2023, covering a novel polynucleotide and method for producing L-alanine, published April 23, 2026. The application discloses biotechnological methods for L-alanine production using the novel polynucleotide, with CPC classifications in C12N 9/1096 and related enzyme categories. Inventors include Ju-Yeon Kim, Min-Jung Kim, and Ji Hye Lee.

Adeno-Associated Virus Variant Patent Application

The USPTO published patent application US20260109956A1 on April 23, 2026, disclosing an adeno-associated virus 2 (AAV2) variant invented by Dong Woo Song and Hyekyung Oh. The application claims VP1 variants comprising amino acid sequences selected from SEQ ID NOS: 02 to 31. Filing date was October 28, 2025, under application number 19371743. The patent application is classified under CPC codes C12N 7/00 and C07K 14/005, placing it within the biotechnology and gene therapy vector arts.

Novozyme Lactase Variants for Dairy, US20260109961A1

USPTO published patent application US20260109961A1, filed 2025-06-06 by Novozymes A/S (Denmark), covering novel lactase enzyme variants with modified galactose inhibition profiles. The variants are described as suitable for producing low-lactose or lactose-free dairy products. CPC classifications include C12N 9/2471 (amylases or glucoinosidases), A23C 9/1206 (lactose reduction), and C12N 15/52/63 (gene sequences and expression vectors). Inventors include Roland Alexander Pache, Anders Gunnar Sandstrom, Jan Kjoelhede Vester, Henrik Friis-Madsen, and Dorota Nissen. As a published application, no enforcement or compliance obligations arise from this document.

Recombinant Endopeptidase Production Method

NEMYSIS LIMITED filed US Patent Application US20260109962A1 on July 2, 2025, covering a method for manufacturing an enzyme preparation comprising recombinant Actinoallomurus endopeptidase with glutenase activity at high yields suitable for human use. The application also discloses a recombinant expression vector, S. lividans host cell comprising said vector, the resulting enzyme preparation, formulations thereof, and clinical uses. Published April 23, 2026.

Novozymes A/S Alpha-Amylase Enzyme Variants and Polynucleotides Patent Application

Novozymes A/S has filed US Patent Application US20260109960A1 (Application No. 19363135) titled 'ENZYME VARIANTS AND POLYNUCLEOTIDES ENCODING THE SAME', published April 23, 2026, with a filing date of October 20, 2025. The application covers polypeptides with alpha-amylase activity, encoding polynucleotides, nucleic acid constructs, vectors, host cells, and associated production methods. CPC classifications include C12N 9/2414, C11D 3/386, and related biotechnological categories indicating commercial applications in cleaning products and industrial enzyme production. Eight named inventors are listed, including Torsten Bak Regueira, Bitten Plesner, Thomas Holberg Blicher, Anne Dorte Houg, Sofia Arnehed, Lars Lehmann Hylling Christensen, and Carsteen Andersen.

Nucleic Acid Purification Using Mixed Mode Resins

USPTO published patent application US20260109965A1 titled 'Purification of Nucleotides by Means of a Mixed-Mode Purification System,' filed September 27, 2023 (Application No. 19115842). The invention relates to purification of nucleotides using mixed mode resins and names four inventors: Jennifer Beaudoin, Matthew J. Burak, Christopher Ladd Effio, and Haripriya Sharma. CPC classifications include C12N 15/101, B01J 20/262, and C12N 15/1017.

Methods of Treating Pulmonary Sarcoidosis With DNA Nucleases

USPTO published patent application US20260109959A1 on April 23, 2026, disclosing methods for treating pulmonary sarcoidosis via inhalation of human recombinant DNase1 or other DNA nucleases. The application, filed January 18, 2025, names inventors Brian William Davies, Daniel S. Cartwright, and Ira Kalfus. The invention proposes that DNA nucleases reduce excessive lung DNA that stimulates TLR9 receptors, thereby decreasing inflammation, cytokine release, and granuloma formation characteristic of sarcoidosis.

Patent Application for Adipocyte Cytotoxic Protein Constructs for Fat Reduction

Matthew Rein Scholz and Gary Charles Hudson filed US Patent Application 19281400 on July 25, 2025, published April 23, 2026, covering polynucleotide constructs that enable adipocyte-specific production of cytotoxic proteins for reducing adipose tissue volume in visceral, subcutaneous, and abdominal fat deposits. The application also discloses lipid-based delivery vectors for administering these constructs. This is a patent application publication (Kind A1), not a granted patent, and does not yet confer any exclusive rights or compliance obligations on third parties.

Non-Piezoelectric Flexible Resonator Promotes Cell Division, Migration

Application US20260109964A1 was filed on August 28, 2025 by inventors Won-gun KOH, Hyungsuk LEE, Donyoung KANG, Byeongseok RYU, Sujeong AHN, and Chanryeol RHYOU, and published on April 23, 2026. The application covers a resonator that promotes cell division and migration using an interdigitated electrode structure deposited on a dielectric polymer substrate surface, generating acoustic waves when alternating current at resonant frequency is applied. The technology is classified under CPC codes C12N 13/00 and C12M 35/04. While the application does not yet grant enforceable rights, it establishes a priority date for the claimed non-piezoelectric flexible resonator technology in the biomedical device space.

Cyto-Facto T Cells for Transplantation and Production Method

Cyto-Facto Inc., with inventors Shin Kawamata and Takako Yamamoto, filed patent application US20260109948A1 for engineered human T cells lacking human leukocyte antigen (HLA) class I molecules and containing an exogenous ST6GALNAC6 gene. The application claims cells characterized by CD62L and CD45RA positivity, with ATP production of at least 400 pmol/min/10^5 cells and mitochondrial spare respiratory capacity of at least 40 pmol/min/10^5 cells, 5-6 days after proliferation stimulation. The invention aims to provide low-immunogenic human T cells capable of long-term engraftment for allogeneic CAR-T or TCR-T cell therapy applications.

Kyoto University Patent for Regulatory T Cell Production Method

Kyoto University published patent application US20260109949A1 on April 23, 2026, covering a method for producing regulatory T cells by culturing CD4+ T cells derived from pluripotent stem cells in the presence of IL-4 and a TGF-βR agonist. The application lists Shin KANEKO, Shoichi IRIGUCHI, Takayuki SATO, and Yoshiaki KASSAI as inventors. The disclosed invention also encompasses the resulting cell population containing proliferated regulatory T cells and a medicine containing that cell population.

Adipose Stem Cells Converted to Hematopoietic Cells

USPTO published patent application US20260109947A1, filed March 11, 2024, for a method of producing hematopoietic stem/progenitor cells (HS/PCs) and blood cells from adipose-derived mesenchymal stem cells (Ad MSCs). The method involves obtaining and expanding biological cells, isolating a pure Ad MSC cell line, converting it to HS/PCs in vitro, and expanding the resulting cells. This publication represents the first entry in the patent record for the named inventors Wei LI, Shaojin YOU, Michael Chengnan LIN, and Annie YOU; no compliance obligations or deadlines are created.

Microglia From Pluripotent Stem Cells

The USPTO published patent application US20260109946A1 on April 23, 2026, covering methods and compositions for generating microglial progenitor cells and microglial cells from pluripotent stem cells. Inventors include Panagiotis Douvaras, Scott Noggle, Stephen Chang, and Valentina Fossati. The application (No. 19423436) was filed on December 17, 2025, and covers both the cell generation methods and applications including methods of treatment and drug screening.

Lung Biotechnology PBC Cell Scaffold Patent Application US20260109952A1

Lung Biotechnology PBC has filed US Patent Application US20260109952A1, published April 23, 2026, for a printable composition used to manufacture cell-receiving scaffolds. The composition comprises approximately 0.3 to 3.0 wt% collagen, 5.0 to 40.0 wt% monomers, 0.5 to 2.0 wt% photoinitiator, and up to 75 wt% protic solvent vehicle. The application claims a printing resolution of 100 microns or less, specific photo speed parameters (Dp/Ec of 0.1-5 mm Dp and 10-100 mJ/cm² Ec), and a green strength of at least 5 kPa after drying. The patent also covers methods for manufacturing three-dimensional cell-receiving scaffolds using the composition. Inventors include Pingyong Xu, Luis Alvarez, Derek Morris, and Iman Yazdi, with filing date December 10, 2025.

Compositions and Methods for Production of Exofucosylated Cells for Clinical Applications

Robert Sackstein filed US20260109950A1 on April 23, 2026, covering compositions and methods for detecting changes in cell-surface Type 2 terminal lactosamine expression levels and for enforcing stably expressed glycans on human cells using α(1,3)-fucosyltransferase family members. The application, filed September 16, 2025 under Application No. 19330402, describes glycoengineered CD44 glycosylated product (HCELL) that remains stable for at least 48 hours at 4°C with retained expression after cell cryopreservation. This is a patent application publication providing public notice of the filed application and establishing priority dates.

CVB1 Purification Method Using Heparin Affinity

Hangzhou Yangshengtang Biopharma Co., Ltd. has filed US Patent Application US20260109955A1 for a method of purifying coxsackievirus B1 (CVB1) using heparin affinity chromatography. The application names Lisheng Yang, Bing Liu, Tianyu Ding, Chengfa Ji, Limin Wang, and Wei Shi as inventors and was published on April 23, 2026. The filing date was November 30, 2023, with application number 18860522.

Xeno-Free PEHA Polymers for 3D Printing Patented

USPTO published patent application US20260109953A1 for xeno-free PEHA polymer hydrogels designed for 3D bioprinting applications, filed April 25, 2023, with inventors Chien-Chi Lin, Nathan H. Dimmitt, and Fang-Yi Lin. The application discloses compositions comprising polymers with at least one BO2H2 repeating unit and methods for encapsulating cells using these hydrogels. This represents prior art for any entities developing similar xeno-free bioink or cell-encapsulation technologies.

Systems and Methods to Protect Biological Cells With Exogenous Lipids

USPTO published patent application US20260109954A1 filed December 17, 2025 (Application No. 19424078) for systems and methods to protect biological cells during in vitro processing. Inventors Lisa A. Herickhoff and Myles Shepherd disclose forming a protective layer with exogenous lipids around cells that interact with plasma membranes, enabling cell preservation and repair during manipulation.

Biostimulant Systems for Nitrogen Use Efficiency

The USPTO has published patent application US20260109940A1 for biostimulant systems to promote nitrogen use efficiency in plants. The application covers methods and systems for producing biostimulants using a bioreactor-based process with nitrogen-efficient microbial strains, filed June 17, 2025, with nine named inventors including Luis Francisco VELAZQUEZ and Robert D CHISHOLM. This published application establishes prior art status and secures the June 2025 filing date for the claimed biostimulant production methods.

CRISPR Cpf1 for Acidithiobacillus Ferrooxidans Genes

Columbia University (The Trustees of Columbia University in the City of New York) has filed a published patent application (US20260109942A1) with the USPTO covering methods and genomic editing systems for Acidithiobacillus ferrooxidans using Cpf1 (Cas12a). The application was filed on October 31, 2025 and published on April 23, 2026. Inventors include Scott Banta, Heejung Jung, and Yuta Inaba.

Cells Resistant to Mobile Genetic Elements

USPTO published patent application US20260109938A1, filed July 19, 2023, covering cells resistant to mobile genetic elements and methods for obtaining them. The invention includes orthogonal genetic code systems designed to prevent horizontal gene transfer, with potential applications in protecting engineered cells and preventing unwanted genetic exchange. Inventors are Jason CHIN, Jerome ZURCHER, and Wesley ROBERTSON.

UV Polymerization Method for Harvesting Microalgae Patent Application

USPTO published patent application US20260109936A1 on April 23, 2026, filed September 28, 2023 under Application No. 19117358. The invention by inventors Long D Nghiem, Peter Ralph, Luong N Nguyen, and Qiang Fu discloses a method for harvesting microalgae involving mixing monomers with a photoinitiator, water, and a deoxygenation system; exposing the mixture to UV light to form polymers; introducing the polymer solution to microalgae suspensions to produce flocculated microalgae; and harvesting the flocculated product. The application also covers a method for preparing and selecting polymeric flocculants and a related apparatus.

Probiotic Preparation Containing Akk11 Strain for Calcium Absorption

USPTO published patent application US20260109939A1, filed June 19, 2024 under application no. 18995236, disclosing a probiotic preparation combining Akkermansia muciniphila Akk11 strain and Bifidobacterium breve BBr16 strain designed to synergistically enhance calcium absorption by improving intestinal health and strengthening the absorption capacity of the intestinal wall. The application claims the preparation can promote serum calcium and phosphorus levels, restore normal electrolyte levels, and reduce calcium loss in bones to stabilize bone structure and function. This is the initial publication of the patent application — no patent has yet been granted.